Akumentis Healthcare, the branded medicines business of Akums Drugs & Pharmaceuticals, reported steady growth in FY26. The company posted an operating revenue of Rs 446 crore and a net profit of Rs 77 crore during the financial year. The latest numbers show that the company continues to strengthen its position in India’s prescription medicines market while its parent company, Akums, expands its business in India and overseas.
The financial performance comes as Akums focuses on increasing its manufacturing capacity, expanding exports, launching new products, and investing in future growth. The company is also working on international partnerships and strengthening its contract development and manufacturing (CDMO) business.
Akumentis Healthcare records steady growth in FY26
Akumentis Healthcare has maintained consistent growth over the last three financial years. The company reported operating revenue of Rs 446 crore in FY26, compared to Rs 434 crore in FY25 and Rs 398 crore in FY24. It also earned a net profit of Rs 77 crore during FY26.
The company sells more than 167 branded prescription medicines across different medical categories, including gynecology, cardiology, orthopedics, pediatrics, and dermatology. Its wide product range has helped it build a strong presence among doctors and healthcare professionals across India.
Akumentis also continues to receive support from investors. Peak XV Partners remains its largest external investor. So far, the company has raised around $19 million in funding, which has helped it grow its product portfolio and expand its business.
The steady financial performance reflects the growing demand for branded medicines in India and supports the overall growth strategy of the Akums Group.
Akums plans expansion with new investments and global deals
Akums Drugs & Pharmaceuticals also reported a strong financial performance for FY26. The company recorded consolidated revenue from operations of Rs 4,359 crore, up 5.9% from the previous year. Adjusted Profit After Tax (PAT) increased by 27.3% to Rs 276 crore, while adjusted EBITDA rose 13.3% to Rs 522 crore. In the fourth quarter alone, EBITDA jumped 61.6% compared to the same period last year.
The company ended the year with a net cash position of more than Rs 1,608 crore. Its board has also recommended a dividend of Rs 3 per share for shareholders.
For FY27, Akums has planned a capital expenditure of Rs 300 crore. The money will be used to expand its oral solid medicine manufacturing facilities, look at merger and acquisition opportunities, and support future growth in its CDMO business.
One of the biggest developments for the company is a long-term agreement worth around €200 million with a global pharmaceutical company. Under the deal, Akums will supply oral liquid medicines to 20 European countries between 2027 and 2032. The company has also received an upfront payment of €100 million, which will be used for product development and regulatory approvals. Its Haridwar manufacturing plants have already received European Good Manufacturing Practice (EU GMP) certification.
Akums is also expanding its presence in Africa through its joint venture in Zambia, where it holds a 51% stake. Commercial supplies from India are expected to begin during CY26 or CY27, while the local manufacturing plant in Zambia is expected to start operations by CY28.
The company has also received approval from the Drugs Controller General of India (DCGI) for India’s first generic room-temperature-stable hydroxyurea oral suspension for the treatment of sickle cell disease. Akums expects strong demand for the product, especially from government healthcare programmes.
Company faces tax demand while continuing business growth
Along with its business expansion, Akums is also dealing with a tax issue. The Income Tax Department has issued a tax demand of Rs 156.01 crore for the period between April 2018 and March 2025. The demand is related to the disallowance of certain business expenses and covers Akums as well as some of its subsidiaries, including Akumentis Healthcare. The company has said it will challenge the order through the legal process.
In another case, a penalty of Rs 3.59 crore imposed on subsidiary Maxcure Nutravedics over an incorrect shipping address was cancelled by the First Appellate Authority, giving relief to the company.
Akums has also returned to full production at its Haridwar manufacturing plants after resolving a short labour issue. The company continues to improve its environmental, social, and governance (ESG) performance by focusing on better energy efficiency and sustainable operations.
The pharmaceutical industry remains highly competitive. Companies like Innova Captab are expanding their manufacturing business through new plants and acquisitions, while InCred Financial Services has reported strong financial growth ahead of its planned IPO.
With steady growth at Akumentis Healthcare, strong financial results at Akums, new international business opportunities, and continued investments, the group is well placed for future growth. While regulatory challenges remain, the company is focusing on expanding its business, increasing exports, and strengthening its position in the pharmaceutical industry.